X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs IPCA LABS - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA IPCA LABS DISHMAN PHARMA/
IPCA LABS
 
P/E (TTM) x 25.1 27.7 90.7% View Chart
P/BV x 3.3 2.1 157.8% View Chart
Dividend Yield % 0.7 0.2 274.2%  

Financials

 DISHMAN PHARMA   IPCA LABS
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
IPCA LABS
Mar-17
DISHMAN PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs374643 58.2%   
Low Rs129503 25.6%   
Sales per share (Unadj.) Rs197.8254.4 77.7%  
Earnings per share (Unadj.) Rs21.216.1 132.0%  
Cash flow per share (Unadj.) Rs34.729.8 116.6%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.80.2 455.3%  
Book value per share (Unadj.) Rs179.9194.6 92.5%  
Shares outstanding (eoy) m80.69126.20 63.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.3 56.5%   
Avg P/E ratio x11.935.7 33.3%  
P/CF ratio (eoy) x7.219.2 37.7%  
Price / Book Value ratio x1.42.9 47.5%  
Dividend payout %9.46.2 151.6%   
Avg Mkt Cap Rs m20,30672,300 28.1%   
No. of employees `0000.813.3 6.2%   
Total wages/salary Rs m5,3556,960 76.9%   
Avg. sales/employee Rs Th19,252.72,413.5 797.7%   
Avg. wages/employee Rs Th6,459.5523.2 1,234.7%   
Avg. net profit/employee Rs Th2,064.1152.4 1,353.9%   
INCOME DATA
Net Sales Rs m15,96132,106 49.7%  
Other income Rs m265226 117.6%   
Total revenues Rs m16,22632,332 50.2%   
Gross profit Rs m4,1034,448 92.3%  
Depreciation Rs m1,0911,730 63.1%   
Interest Rs m944241 392.2%   
Profit before tax Rs m2,3342,703 86.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624675 92.4%   
Profit after tax Rs m1,7112,028 84.4%  
Gross profit margin %25.713.9 185.6%  
Effective tax rate %26.725.0 107.0%   
Net profit margin %10.76.3 169.7%  
BALANCE SHEET DATA
Current assets Rs m11,01817,340 63.5%   
Current liabilities Rs m9,5179,559 99.6%   
Net working cap to sales %9.424.2 38.8%  
Current ratio x1.21.8 63.8%  
Inventory Days Days110100 110.2%  
Debtors Days Days3557 61.3%  
Net fixed assets Rs m16,30420,779 78.5%   
Share capital Rs m161252 63.9%   
"Free" reserves Rs m12,90724,499 52.7%   
Net worth Rs m14,51624,553 59.1%   
Long term debt Rs m4,1893,517 119.1%   
Total assets Rs m29,80539,595 75.3%  
Interest coverage x3.512.2 28.4%   
Debt to equity ratio x0.30.1 201.5%  
Sales to assets ratio x0.50.8 66.0%   
Return on assets %8.95.7 155.5%  
Return on equity %11.88.3 142.7%  
Return on capital %17.510.5 167.1%  
Exports to sales %24.848.6 51.0%   
Imports to sales %3.714.2 26.2%   
Exports (fob) Rs m3,95615,617 25.3%   
Imports (cif) Rs m5964,571 13.0%   
Fx inflow Rs m4,95215,617 31.7%   
Fx outflow Rs m6975,828 12.0%   
Net fx Rs m4,2559,790 43.5%   
CASH FLOW
From Operations Rs m2,7862,764 100.8%  
From Investments Rs m-1,529-1,432 106.8%  
From Financial Activity Rs m-941-1,591 59.1%  
Net Cashflow Rs m316-259 -122.3%  

Share Holding

Indian Promoters % 61.4 45.9 133.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 11.4 32.5%  
FIIs % 12.7 25.3 50.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 17.4 127.0%  
Shareholders   46,261 36,892 125.4%  
Pledged promoter(s) holding % 35.8 2.1 1,671.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   SHASUN PHARMA  DR. REDDYS LAB  ABBOTT INDIA  UNICHEM LAB  WYETH LTD  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS